Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Return on equity
Zoetis Inc.'s return on equity over the twelve months to 30 June 2026 was 64.9%, down 1.1 percentage points from fiscal 2025 (66.0%). Over the past ten years it has ranged from 27.9% (fiscal 2015) to 71.9% (fiscal 2018); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.40% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 66.0% | 15.05 |
| FY2024 | 50.9% | 1.04 |
| FY2023 | 49.9% | 2.64 |
| FY2022 | 47.3% | (1.72) |
| FY2021 | 49.0% | (1.57) |
| FY2020 | 50.6% | (10.76) |
| FY2019 | 61.3% | (10.61) |
| FY2018 | 71.9% | 19.32 |
| FY2017 | 52.6% | (10.80) |
| FY2016 | 63.4% | 35.48 |
Against its own ten years
Low 27.9%
High 71.9%
Ten-year median
50.9%
Current reading's percentile
91
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 22.1% |
| UTHR United Therapeutics Corporation compare | 19.3% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 9.69% |
| RDY Dr. Reddy's Laboratories Ltd compare | 8.21% |
| TAK Takeda Pharmaceutical Co. compare | 4.42% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. compare | −2.75% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| Drug Manufacturers Specialty & Generic industry median | −0.40% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement